EA013225B1 - Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток - Google Patents

Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток Download PDF

Info

Publication number
EA013225B1
EA013225B1 EA200501101A EA200501101A EA013225B1 EA 013225 B1 EA013225 B1 EA 013225B1 EA 200501101 A EA200501101 A EA 200501101A EA 200501101 A EA200501101 A EA 200501101A EA 013225 B1 EA013225 B1 EA 013225B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
nucleic acid
polyclonal
library
cell
Prior art date
Application number
EA200501101A
Other languages
English (en)
Russian (ru)
Other versions
EA200501101A1 (ru
Inventor
Джон С. Хаурум
Финн К. Виберг
Винсент В. Колье
Жаклин Шарон
Чиоу-Ин Ян
Original Assignee
Симфоген А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Симфоген А/С filed Critical Симфоген А/С
Publication of EA200501101A1 publication Critical patent/EA200501101A1/ru
Publication of EA013225B1 publication Critical patent/EA013225B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
EA200501101A 2003-01-07 2004-01-07 Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток EA013225B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43840303P 2003-01-07 2003-01-07
DKPA200300008 2003-01-07
US47601803P 2003-06-05 2003-06-05
PCT/DK2004/000001 WO2004061104A2 (en) 2003-01-07 2004-01-07 Method for manufacturing recombinant polyclonal proteins

Publications (2)

Publication Number Publication Date
EA200501101A1 EA200501101A1 (ru) 2006-02-24
EA013225B1 true EA013225B1 (ru) 2010-04-30

Family

ID=32718469

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501101A EA013225B1 (ru) 2003-01-07 2004-01-07 Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток

Country Status (18)

Country Link
US (1) US9163232B2 (enExample)
EP (2) EP1583830B1 (enExample)
JP (2) JP4589914B2 (enExample)
KR (1) KR101024443B1 (enExample)
AT (1) ATE338816T1 (enExample)
AU (1) AU2004203727C1 (enExample)
BR (1) BRPI0406678A (enExample)
CA (1) CA2512647C (enExample)
DE (1) DE602004002275T2 (enExample)
DK (1) DK1583830T3 (enExample)
EA (1) EA013225B1 (enExample)
ES (1) ES2273202T3 (enExample)
IL (1) IL169101A (enExample)
MX (1) MXPA05006724A (enExample)
NZ (1) NZ541458A (enExample)
PT (1) PT1583830E (enExample)
SI (1) SI1583830T1 (enExample)
WO (1) WO2004061104A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11795579B2 (en) 2017-12-11 2023-10-24 Abalone Bio, Inc. Yeast display of proteins in the periplasmic space

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
JP4926054B2 (ja) * 2004-07-20 2012-05-09 シムフォゲン・アクティーゼルスカブ 抗−ＲｈＤ組換えポリクローナル抗体及び製造方法
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
EP1907561B1 (en) * 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
WO2007065433A2 (en) 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
US20100040606A1 (en) * 2006-03-06 2010-02-18 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
FR2910490B1 (fr) * 2006-12-20 2012-10-26 Lab Francais Du Fractionnement Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
TW200846362A (en) * 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
BRPI0808551B1 (pt) 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
NZ578851A (en) 2007-03-01 2011-09-30 Symphogen As Method for cloning cognate antibodies
CA2678628A1 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
BRPI0812091A2 (pt) 2007-05-25 2014-10-14 Symphogen As Método para fabricar uma proteína policlonal recombinante
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
WO2009046168A1 (en) 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
CN108130327A (zh) 2007-10-11 2018-06-08 第三共株式会社 靶向破骨细胞相关蛋白Siglec-15的抗体
RU2010147652A (ru) * 2008-04-23 2012-05-27 Симфоген А/С (Dk) Способы производства поликлонального белка
CA2735020A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
MX2011001927A (es) 2008-08-29 2011-04-21 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
EP2377932B1 (en) 2009-04-09 2020-11-18 Daiichi Sankyo Company, Limited ANTI-Siglec-15 ANTIBODY
AU2010306563B2 (en) 2009-10-15 2013-11-28 Circle 33, Llc Antibody therapeutics with local activity in the digestive tract
BR112013010574A2 (pt) 2010-10-29 2016-08-09 Daiichi Sankyo Co Ltd anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo
WO2012059857A2 (en) 2010-11-01 2012-05-10 Symphogen A/S Pan-her antibody composition
JP6092782B2 (ja) * 2010-11-16 2017-03-08 エクセリミューン， インコーポレイテッド 組換えタンパク質の製造方法
EP2703486B1 (en) 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
CN107881196A (zh) 2011-12-22 2018-04-06 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9464133B2 (en) 2012-03-30 2016-10-11 Daiichi Sankyo Company, Limited CDR-modified anti-Siglec-15 antibody
JPWO2013147212A1 (ja) 2012-03-30 2015-12-14 第一三共株式会社 新規抗Ｓｉｇｌｅｃ−１５抗体
AU2013247645B2 (en) 2012-04-09 2019-02-14 Daiichi Sankyo Company, Limited Anti-FGFR2 antibody
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
IN2014DN07799A (enExample) 2012-04-27 2015-05-15 Daiichi Sankyo Co Ltd
HK1202431A1 (en) 2012-05-02 2015-10-02 Symphogen A/S Humanized pan-her antibody compositions
JP2015163047A (ja) * 2012-06-20 2015-09-10 国立大学法人 東京大学 タンパク質の迅速改良法
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
JP2016514091A (ja) 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
CA2925897A1 (en) 2013-09-30 2015-04-02 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
CN105792844B (zh) 2013-10-08 2021-03-02 第一三共株式会社 抗fgfr2抗体和另一药剂的组合
WO2015093925A1 (es) * 2013-12-19 2015-06-25 CASTRO ALDRETE, Jorge Isaac Método de producción de anticuerpos específicos
DK3805268T3 (da) 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
MX378108B (es) 2014-09-16 2025-03-10 Servier Lab Anticuerpos anti-met y composiciones.
EP3273994B1 (en) 2015-03-27 2021-12-01 University of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
CA2987992A1 (en) 2015-06-04 2016-12-08 University Of Southern California Lym-1 and lym-2 targeted car cell immunotherapy
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
JP7054924B2 (ja) 2015-09-23 2022-04-15 サイトイミューン セラピューティクス， インコーポレイテッド 免疫療法のためのｆｌｔ３指向ｃａｒ細胞
CN110922481A (zh) 2015-09-24 2020-03-27 第一三共株式会社 抗garp抗体
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
EP3235516B1 (en) 2016-04-22 2019-06-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Regulatable adeno-associated virus (aav) vector
CA3025162A1 (en) * 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
CN118126180A (zh) 2016-12-22 2024-06-04 第一三共株式会社 抗cd3抗体和包含所述抗体的分子
TW201837174A (zh) 2017-02-07 2018-10-16 日商第一三共股份有限公司 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
AU2018247916B2 (en) 2017-04-05 2025-04-24 Les Laboratoires Servier Combination therapies targeting PD-1, TIM-3, and LAG-3
EP3625264B9 (en) 2017-05-17 2023-10-25 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
US20200115446A1 (en) 2017-06-30 2020-04-16 National University Corporation Hokkaido University Pediatric osteoporosis drug that does not cause growth disorder
CA3071234A1 (en) 2017-07-27 2019-01-31 Daiichi Sankyo Company, Limited Anti-cd147 antibody
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
BR112020006860A2 (pt) 2017-10-05 2020-10-20 Daiichi Sankyo Company, Limited composição para depleção de células t citotóxicas
CN111836643A (zh) 2018-03-05 2020-10-27 学校法人埼玉医科大学 用于治疗或预防异位骨化的药物组合物
CN118126182A (zh) 2018-05-31 2024-06-04 第一三共株式会社 抗人tlr7抗体
US12247065B2 (en) 2018-06-22 2025-03-11 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
MX2020013068A (es) 2018-07-10 2021-03-02 Univ Kobe Nat Univ Corp Anticuerpo anti proteína reguladora de señales alfa sirpalfana.
EP3831853A4 (en) 2018-07-27 2022-06-01 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT
KR102559149B1 (ko) * 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
JP2022531113A (ja) 2019-04-30 2022-07-06 ギガジェン，インコーポレイティッド 組換えポリクローナルタンパク質およびその使用方法
EP4008350A4 (en) 2019-07-26 2023-06-14 Saitama Medical University ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1
CN114630679A (zh) 2019-10-25 2022-06-14 第一三共株式会社 抗garp抗体和免疫调节剂的组合
WO2021136835A1 (en) 2019-12-31 2021-07-08 Antagonis Compositions and methods for the prevention of s. aureus infection
WO2021253002A1 (en) 2020-06-12 2021-12-16 Gigagen, Inc. Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2022031834A1 (en) 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof
EP4204005A1 (en) 2020-08-31 2023-07-05 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
AU2024277829A1 (en) 2023-05-19 2025-12-04 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677177A (en) * 1991-03-08 1997-10-14 The Salk Institute For Biological Studies FLP-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US5789208A (en) * 1994-01-31 1998-08-04 The Trustees Of Boston University Polyclonal antibody libraries
WO1998041645A1 (en) * 1997-03-14 1998-09-24 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
WO2000011155A1 (en) * 1998-08-19 2000-03-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
WO2001089563A1 (en) * 2000-05-26 2001-11-29 Symphogen A/S Recombinant or purified polyclonal antibodies for treating allergy
WO2002044361A2 (en) * 2000-11-28 2002-06-06 Applied Molecular Evolution, Inc. Eukaryotic expression libraries based on double lox recombination and methods of use
WO2002055718A2 (en) * 2000-10-31 2002-07-18 Genetastix Corp Assembly and screening of highly complex and fully human antibody repertoire in yeast

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155114A (en) * 1874-09-15 Improvement in methods of laying and forming cast-iron pipes
CA1293460C (en) * 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
WO1991016074A1 (en) 1990-04-19 1991-10-31 Medimmune, Inc. Administration of monoclonal antibodies against respiratory viruses
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US6368821B1 (en) 1997-04-14 2002-04-09 Stratagene Process for infecting eukaryotic cells with a bacterial virus
US20020155114A1 (en) 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6410317B1 (en) 1999-07-14 2002-06-25 Clontech Laboratories, Inc. Recombinase-based methods for producing expression vectors and compositions for use in practicing the same
DE60044142D1 (de) 1999-07-23 2010-05-20 Univ California Dna-rekombination in eukaryotischen zellen mittels des rekombinationszentrums vom bakteriophag phic31
EP1293564A4 (en) 2000-06-08 2005-08-17 Mitsubishi Pharma Corp EXPRESSION VECTOR FOR SCREENING CELLS HIGH EXPRESSION OF RECOMBINANT PROTEINS, TRANSFORMING HIGH EXPRESSION OF A RECOMBINANT PROTEIN AND USE THEREOF
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US20030044398A1 (en) 2001-03-20 2003-03-06 Robl James M. Methods for producing antibodies in mammals
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US20040115814A1 (en) 2002-09-30 2004-06-17 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
US20060275766A1 (en) 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
JP2007535913A (ja) 2004-01-21 2007-12-13 ノボザイムス アクティーゼルスカブ ヘテロカリオン菌類又は菌類宿主細胞におけるモノクローナル抗体の生成
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
JP4926054B2 (ja) 2004-07-20 2012-05-09 シムフォゲン・アクティーゼルスカブ 抗−ＲｈＤ組換えポリクローナル抗体及び製造方法
WO2007065433A2 (en) 2005-12-05 2007-06-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
US20100040606A1 (en) 2006-03-06 2010-02-18 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
TW200846362A (en) 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
BRPI0812091A2 (pt) 2007-05-25 2014-10-14 Symphogen As Método para fabricar uma proteína policlonal recombinante

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677177A (en) * 1991-03-08 1997-10-14 The Salk Institute For Biological Studies FLP-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US5789208A (en) * 1994-01-31 1998-08-04 The Trustees Of Boston University Polyclonal antibody libraries
WO1998041645A1 (en) * 1997-03-14 1998-09-24 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
WO2000011155A1 (en) * 1998-08-19 2000-03-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
WO2001089563A1 (en) * 2000-05-26 2001-11-29 Symphogen A/S Recombinant or purified polyclonal antibodies for treating allergy
WO2002055718A2 (en) * 2000-10-31 2002-07-18 Genetastix Corp Assembly and screening of highly complex and fully human antibody repertoire in yeast
WO2002044361A2 (en) * 2000-11-28 2002-06-06 Applied Molecular Evolution, Inc. Eukaryotic expression libraries based on double lox recombination and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SODERLIND E. ET AL.: "Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries", NATURE BIOTECHNOLOGY, vol. 18, no. 8, August 2000 (2000-08), pages 852-856, XP002242392, ISSN: 1087-0156, cited in the application, the whole document *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11795579B2 (en) 2017-12-11 2023-10-24 Abalone Bio, Inc. Yeast display of proteins in the periplasmic space

Also Published As

Publication number Publication date
EP1583830A2 (en) 2005-10-12
MXPA05006724A (es) 2005-09-08
AU2004203727A1 (en) 2004-07-22
CA2512647C (en) 2013-10-08
EP1583830B1 (en) 2006-09-06
KR20050101538A (ko) 2005-10-24
BRPI0406678A (pt) 2005-12-20
CA2512647A1 (en) 2004-07-22
HK1078896A1 (en) 2006-03-24
ES2273202T3 (es) 2007-05-01
DE602004002275D1 (de) 2006-10-19
DK1583830T3 (da) 2007-01-15
JP4589914B2 (ja) 2010-12-01
DE602004002275T2 (de) 2007-09-06
US9163232B2 (en) 2015-10-20
SI1583830T1 (sl) 2006-12-31
ATE338816T1 (de) 2006-09-15
NZ541458A (en) 2006-04-28
JP2006515520A (ja) 2006-06-01
AU2004203727B2 (en) 2008-01-31
PT1583830E (pt) 2006-11-30
AU2004203727C1 (en) 2008-08-21
KR101024443B1 (ko) 2011-03-23
WO2004061104A2 (en) 2004-07-22
EP1762617A1 (en) 2007-03-14
US20090136498A1 (en) 2009-05-28
WO2004061104A3 (en) 2004-11-04
EA200501101A1 (ru) 2006-02-24
IL169101A (en) 2009-02-11
JP2010268806A (ja) 2010-12-02

Similar Documents

Publication Publication Date Title
AU2004203727B2 (en) Method for manufacturing recombinant polyclonal proteins
EP2152872B1 (en) Method for manufacturing a recombinant polyclonal protein
US20110117605A1 (en) Methods for Manufacturing a Polyclonal Protein
MX2007000644A (es) Anticuerpo policlonal recombinante anti-rhesus d y metodos de fabricacion.
US20060275766A1 (en) Method for manufacturing recombinant polyclonal proteins
CN100383244C (zh) 用于生产重组多克隆蛋白质的方法
HK1078896B (en) Method for manufacturing recombinant polyclonal proteins
AU2008201796A1 (en) Method for manufacturing recombinant polyclonal proteins
HK1134519B (en) Method for manufacturing a recombinant polyclonal protein

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU